What is Strongbridge Biopharma Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Strongbridge Biopharma's interest expense for the
three
months ended in Jun. 2021 was $ -0.81 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Jun. 2021 was $-2.68 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Strongbridge Biopharma's Operating Income for the
three
months ended in Jun. 2021 was $ -13.07 Mil. Strongbridge Biopharma's Interest Expense for the
three
months ended in Jun. 2021 was $ -0.81 Mil.
Strongbridge Biopharma did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Strongbridge Biopharma Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strongbridge Biopharma (NAS:SBBP) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Strongbridge Biopharma's Interest Expense for the
three
months ended in Jun. 2021 was $-0.81 Mil. Its
Operating Income
for the
three
months ended in Jun. 2021 was $-13.07 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Jun. 2021 was $17.00 Mil.
Strongbridge Biopharma's Interest Coverage for the quarter that ended in Jun. 2021 is calculated as
| Strongbridge Biopharma did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Strongbridge Biopharma (Strongbridge Biopharma) Business Description
Traded in Other Exchanges
N/A
Address
900 Northbrook Drive, Suite 200, Trevose, PA, USA, 19053
Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.
Executives
| David N Gill |
director |
C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843 |
| Cdk Associates, L.l.c. |
10 percent owner |
C/O CAXTON CORPORATION, 731 ALEXANDER ROAD, BUILDING #2, PRINCETON NJ 08540 |
| Bruce Kovner |
10 percent owner |
C/O CAXTON ASSOCIATES, 500 PARK AVENUE, NEW YORK NY 10022 |
| Caxton Corp |
10 percent owner |
731 ALEXANDER ROAD, BUILDING 2, SUITE 500, PRINCETON NJ 08540 |
| John Johnson |
director, officer: Chief Executive Officer |
DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101 |
| Garheng Kong |
director |
712 COLLEGE AVENUE, MENLO PARK CA 94025 |
| Jeffrey W Sherman |
director |
C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618 |
| Marten Steen |
director |
60 LEVERONI COURT, NOVATO CA 94949 |
| Hilde H Steineger |
director |
900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053 |
| Stephen J Long |
officer: Chief Legal Officer |
C R BARD INC 730 CENTRAL AVENUE MURRAY HILL NJ 07974 |
| Fredric J. Cohen |
officer: Chief Medical Officer |
900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053 |
| Scott L. Wilhoit |
officer: Chief Commercial Officer |
900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053 |
| Robert Matthew Lutz |
officer: Chief Financial Officer |
900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053 |
| Richard S Kollender |
officer: Chief Operating Officer |
C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868 |
| A Brian Davis |
officer: Chief Financial Officer |
C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Strongbridge Biopharma (Strongbridge Biopharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SBBP has been successfully added to your 